EC Healthcare Included as an Eligible Stock of the Shenzhen - Hong Kong Stock Connect EC Healthcare Mar 07, 2022 12:45 HKT/SGT Read More
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 Eisai Mar 07, 2022 11:50 JST Read More
Fujitsu and Tokyo Medical and Dental University leverage world's fastest supercomputer and AI technology for scientific discovery to shed light on drug resistance in cancer treatment Fujitsu Ltd Mar 07, 2022 09:21 HKT/SGT Read More
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets Altamira Therapeutics Mar 04, 2022 22:30 HKT/SGT Read More
Altamira Therapeutics 與 Nuance Pharma 優銳醫藥簽署獨家協議,在中國及部分亞洲市場共同開發和商業化Bentrio(TM) 鼻噴劑 Altamira Therapeutics Mar 04, 2022 22:30 HKT/SGT Read More
Altamira Therapeutics 与 Nuance Pharma 优锐医药签署独家协议,在中国及部分亚洲市场共同开发和商业化Bentrio(TM) 鼻喷剂 Altamira Therapeutics Mar 04, 2022 22:30 HKT/SGT Read More
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 Eisai Mar 04, 2022 12:00 JST Read More
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab Eisai Mar 04, 2022 10:05 HKT/SGT Read More
Oculis 获Accure Therapeutics授权引进用于治疗青光眼的神经保护候选药物 进一步强化集团的领先眼科产品线 Oculis S.A. Mar 02, 2022 20:49 HKT/SGT Read More
Oculis獲Accure Therapeutics授權引進用於治療青光眼的神經保護候選藥物 進一步強化集團的領先眼科產品線 Oculis S.A. Mar 02, 2022 20:48 HKT/SGT Read More
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics Oculis S.A. Mar 02, 2022 20:47 HKT/SGT Read More
Avance Clinical Announces New Office Opening in Sydney Avance Clinical Mar 02, 2022 15:00 HKT/SGT Read More